en · de · es · fr · pt
cjc-1295-notes.peptides5388.com › Faq › Persistence, Stability And Measurement — Background and Details

Persistence, Stability And Measurement — Background and Details

By Editorial Desk · published 2026-07-27 · last reviewed 2026-08-01 · Faq

A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Cjc-1295 at a glance

PropertyValueNotes
Molecular massApproximately 3.4 to 3.6 kDaDepends on whether the affinity complex is attached
AppearanceWhite to off-white lyophilized powderFreeze-dried solid, often in a sealed vial
SolubilitySoluble in water and aqueous buffersDissolution rate varies with pH and buffer salt
Typical storageBelow minus 20 degrees Celsius, dry and darkDissolved material is usually kept cold and used promptly
Common analytical methodsReversed-phase HPLC and mass spectrometryPeptide mapping and amino acid analysis add sequence detail

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Related pages on this site

Background and Molecular Design

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Supporting material

=== Preparatory phase === The first five steps of glycolysis are regarded as the preparatory (or investment) phase, since they consume energy to convert the glucose into two three-carbon sugar phosphates (G3P).

At the insistence of the Soviet Union, on 10 October the withdrawal of Bulgarian troops from the parts of Macedonia and Thrace that had been in Greece and Yugoslavia until the war began. On 28 October 1944, a delegation led by Foreign Minister Petko Staynov and including Ministers Nikola Petkov, Dobri Terpeshev and Petko Stoyanov signed an armistice with the Allies. Bulgaria was forced to accept harsh conditions - maintenance of the Soviet troops stationed in the country, placing the government under the control of the Allied Control Commission, and involvement in the hostilities against Germany. On 3 December, at the suggestion of Damyan Velchev, the Council of Ministers passed a decree enabling the military officers charged under the People's Court Act to go to the front and, if they showed bravery, be discharged. The next day the Communists declared the decree "counter-revolutionary" and organised demonstrations against it, and on 6 December, at the insistence of the head of the Union Control Commission, Sergei Biryuzov, the decree was revoked. In the following days, Communists and Soviet officers headed the General Staff and its Intelligence Department, and held two deputy ministerial posts in the War Ministry. On 26 January 1945, the Council of Ministers approved the "Ordinance-Law for the Protection of People's Power", which contained 18 articles - 5 of them providing for the death penalty and 4 for life imprisonment.

van Heyningen, professor emeritus, University of Oxford, UK, and John R. Seal, former scientific director, National Institute of Allergy and Infectious Diseases, Bethesda, note that De's paper "deserves to go down as a classic in the history of cholera, and, indeed, as later developments have shown, in the history of cellular physiology and biochemistry." Thanks to De's discovery of the cholera enterotoxin, research has been redirected to find a vaccine that will spark the immune system to fight the enterotoxin specifically, rather than the bacteria. De and colleagues also published highly cited pioneering studies on V. cholerae action on the intestinal membrane.,, The 1953 paper “An experimental study of the mechanism of action of Vibrio cholerae on the intestinal mucous membrane” is De’s most-cited paper, cited 340 times until August 1986. It was especially influential on research fronts on "E. coli and Vibrio cholerae enterotoxin: detection, characterization, and role of adherence" and "Characterization of cholera enterotoxin and other enterotoxins". John Craig of State University of New York Health Science Center at Brooklyn described De’s work as truly creative and novel, having “forever altered our concepts surrounding the pathogenesis of secretory diarrhoea.” These findings resulted from work he conducted at the Nilratan Sircar Medical College, Calcutta Medical College, and Bose Institute in Kolkata. His research used relatively simple and inexpensive methods. In the words of Nobel Laureate Prof.

Beginning in 2021, the OECD expanded its terminology, stating that "PFAS are defined as fluorinated substances that contain at least one fully fluorinated methyl or methylene carbon atom (without any H/Cl/Br/I atom attached to it), i.e., with a few noted exceptions, any chemical with at least a perfluorinated methyl group (−CF3) or a perfluorinated methylene group (−CF2−) is a PFAS." The United States Environmental Protection Agency (EPA) defines PFAS more narrowly in the Drinking Water Contaminant Candidate List 5 as substances that contain "at least one of the following three structures: R−CF2−CF(R')R", where both the −CF2− and −CF− moieties are saturated carbons, and none of the R groups can be hydrogen; R−CF2−O−CF2−(R'), where both the −CF2− moieties are saturated carbons, and none of the R groups can be hydrogen; or CF3−C−(CF3)RR', where all the carbons are saturated, and none of the R groups can be hydrogen. A summary table of some PFAS definitions is provided in Hammel et al (2022).

Sources: en.wikipedia.org

Notes from published material

== Eluotropic series == An eluotropic series is a list of solvents ordered by their eluting power relative to a fixed adsorbent and a fixed analyte. The "eluting power" of a solvent is largely a measure of how well the solvent can "pull" an analyte off the adsorbent to which it is attached. This often happens when the eluent itself adsorbs onto the stationary phase, displacing the analyte. Such series are useful for determining necessary solvents needed for chromatography of chemical compounds. In general, when the adsorbent is polar (as in normal-phase liquid chromatography), the non-polar solvents such as n-hexane have low eluting power, and polar solvents such as ethanol, methanol or water have high eluting power.

=== Indonesia === The Just and Prosperous People's Party of the Advanced Indonesia Coalition condemned the U.S. strikes in Venezuela and denounced it as "vulgar aggression". The National Awakening Party of the Advanced Indonesia Coalition, through its faction in the House of Representatives condemned the U.S. strikes and accused Donald Trump of using the "law of the jungle" which can be set by other advanced, developed powers to force developing states into capitulation, leading to "modern-era imperialism and colonization". The Prosperous Justice Party through its faction in the House of Representatives condemned the U.S. strikes as an illegal act against the legitimate Venezuelan government and warned that this can set a precedence for future illegal acts committed by a powerful ruling government of a state against the government of their rival states or neighboring states.

The lack of regulations against illicit financial activities prompted the Financial Action Task Force (FATF) to place the Gulf country on its grey list in March 2022. Consequently, the UAE remained a safe option for the criminals. Nearly two-thirds of the Albanian criminal groups, who were active in trade of drugs like cocaine, were believed to be hiding in the UAE. One such individual, Eldi Dizdari was accused of international drug trafficking and was living in Dubai. Research revealed that these criminals invested huge amounts in UAE real estate and other economic sectors to live there. Another trafficker of cocaine from Bosnia, Edin Gačanin, was living in the UAE using his extensive profits to buy property and protection in the country. Dubbed as the "European Escobar", he connected the supply network between production markets of Latin America and consumer markets of Western Europe. He was able to evade the arrest and investigations, including by the US Drug Enforcement Administration, by seeking shelter in the UAE.

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between the forms with and without a drug affinity complex?

The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.

Is CJC-1295 the same as MOD GRF 1-29?

In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.

How is the compound identified in a laboratory?

Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network